Home » Stocks » PHAT

Phathom Pharmaceuticals, Inc. (PHAT)

Stock Price: $33.99 USD -1.09 (-3.11%)
Updated May 13, 2021 4:00 PM EDT - Market closed
Market Cap 987.22M
Revenue (ttm) n/a
Net Income (ttm) -143.77M
Shares Out 28.52M
EPS (ttm) -23.02
PE Ratio n/a
Forward PE n/a
Dividend n/a
Dividend Yield n/a
Trading Day May 13
Last Price $33.99
Previous Close $35.08
Change ($) -1.09
Change (%) -3.11%
Day's Open 35.33
Day's Range 33.29 - 35.90
Day's Volume 59,040
52-Week Range 28.10 - 64.54

News

Hide News
  • All
  • Videos
  • Press Releases
  • Conversation

FLORHAM PARK, N.J., May 11, 2021 (GLOBE NEWSWIRE) -- Phathom Pharmaceuticals, Inc. (Nasdaq: PHAT), a late clinical-stage biopharmaceutical company focused on developing and commercializing novel treatme...

2 days ago - GlobeNewsWire

FLORHAM PARK, N.J., May 06, 2021 (GLOBE NEWSWIRE) -- Phathom Pharmaceuticals, Inc. (Nasdaq: PHAT), a late clinical-stage biopharmaceutical company focused on developing and commercializing novel treatme...

1 week ago - GlobeNewsWire

FLORHAM PARK, N.J., April 29, 2021 (GLOBE NEWSWIRE) -- Phathom Pharmaceuticals, Inc. (Nasdaq: PHAT), a late clinical-stage biopharmaceutical company focused on developing and commercializing novel treat...

2 weeks ago - GlobeNewsWire

FLORHAM PARK, N.J., April 06, 2021 (GLOBE NEWSWIRE) -- Phathom Pharmaceuticals, Inc. (Nasdaq: PHAT), a late clinical-stage biopharmaceutical company focused on developing and commercializing novel treat...

1 month ago - GlobeNewsWire

FLORHAM PARK, N.J., March 30, 2021 (GLOBE NEWSWIRE) -- Phathom Pharmaceuticals, Inc. (Nasdaq: PHAT), a late clinical-stage biopharmaceutical company focused on developing and commercializing novel treat...

1 month ago - GlobeNewsWire

Mustang Bio (NASDAQ: MBIO) shares are trading higher after the company announced the FDA has lifted the clinical hold for its pivotal phase 2 MB-107 clinical trial. The company plans to enroll the first...

Other stocks mentioned: MBIO, BNGO, IMVT
3 months ago - Benzinga

FLORHAM PARK, N.J., Jan. 19, 2021 (GLOBE NEWSWIRE) -- Phathom Pharmaceuticals, Inc. (Nasdaq: PHAT), a late clinical-stage biopharmaceutical company focused on developing and commercializing novel treatm...

3 months ago - GlobeNewsWire

MENLO PARK, Calif.--(BUSINESS WIRE)--Frazier Healthcare Partners announced the promotion of several members on its Life Sciences team: Aditya Kohli to Venture Partner, Anna Chen to Vice President, and M...

Other stocks mentioned: PASG
4 months ago - Business Wire

FLORHAM PARK, N.J., Dec. 16, 2020 (GLOBE NEWSWIRE) -- Phathom Pharmaceuticals, Inc. (Nasdaq: PHAT), a late clinical-stage biopharmaceutical company focused on developing and commercializing novel treatm...

4 months ago - GlobeNewsWire

FLORHAM PARK, N.J., Dec. 15, 2020 (GLOBE NEWSWIRE) -- Phathom Pharmaceuticals, Inc. (Nasdaq: PHAT), a late clinical-stage biopharmaceutical company focused on developing and commercializing novel treatm...

4 months ago - GlobeNewsWire

Management and Key Opinion Leaders to discuss NERD and the vonoprazan NERD development program during virtual Investor Day webcast today at 1:00 PM (ET) Management and Key Opinion Leaders to discuss NER...

4 months ago - GlobeNewsWire

Phathom Pharmaceuticals (PHAT) saw a big move last session, as its shares jumped nearly 7% on the day, amid huge volumes.

5 months ago - Zacks Investment Research

Topline results expected in second half of 2021 Topline results expected in second half of 2021

5 months ago - GlobeNewsWire

FLORHAM PARK, N.J., Nov. 27, 2020 (GLOBE NEWSWIRE) -- Phathom Pharmaceuticals, Inc. (Nasdaq: PHAT), a late clinical-stage biopharmaceutical company focused on developing and commercializing novel treatm...

5 months ago - GlobeNewsWire

FLORHAM PARK, N.J., Nov. 19, 2020 (GLOBE NEWSWIRE) -- Phathom Pharmaceuticals, Inc. (Nasdaq: PHAT), a late clinical-stage biopharmaceutical company focused on developing and commercializing novel treatm...

5 months ago - GlobeNewsWire

FLORHAM PARK, N.J., Nov. 13, 2020 (GLOBE NEWSWIRE) -- Phathom Pharmaceuticals, Inc. (Nasdaq: PHAT), a late clinical-stage biopharmaceutical company focused on developing and commercializing novel treatm...

6 months ago - GlobeNewsWire

FLORHAM PARK, N.J., Sept. 09, 2020 (GLOBE NEWSWIRE) -- Phathom Pharmaceuticals, Inc. (Nasdaq: PHAT), a late clinical-stage biopharmaceutical company focused on developing and commercializing novel tre...

8 months ago - GlobeNewsWire

FLORHAM PARK, N.J., Aug. 06, 2020 (GLOBE NEWSWIRE) -- Phathom Pharmaceuticals, Inc. (Nasdaq: PHAT), a late clinical-stage biopharmaceutical company focused on developing and commercializing novel trea...

9 months ago - GlobeNewsWire

FLORHAM PARK, N.J., July 13, 2020 (GLOBE NEWSWIRE) -- Phathom Pharmaceuticals, Inc. (Nasdaq: PHAT), a late clinical-stage biopharmaceutical company focused on developing and commercializing novel trea...

10 months ago - GlobeNewsWire

First New Patients Randomized in PHALCON-EE and PHALCON-HP Trials Since Temporary Pause Announced in March First New Patients Randomized in PHALCON-EE and PHALCON-HP Trials Since Temporary Pause Announc...

10 months ago - GlobeNewsWire

FLORHAM PARK, N.J., May 12, 2020 (GLOBE NEWSWIRE) -- Phathom Pharmaceuticals, Inc. (Nasdaq: PHAT), a late clinical-stage biopharmaceutical company focused on developing and commercializing novel treat...

1 year ago - GlobeNewsWire

Phathom Pharmaceuticals: A Clinical-Stage Company With A De-Risked Pipeline For 2020

1 year ago - Seeking Alpha

About PHAT

Phathom Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing treatments for gastrointestinal diseases. The company has the rights in the United States, Europe, and Canada to vonoprazan, a potassium-competitive acid blocker (P-CAB) that blocks acid secretion in the stomach. It is also developing vonoprazan, which is in Phase III clinical trials for the treatment of erosive gastroesophageal reflux disease; and in combination with antibiotics for the treatment of Helicobacter pylori infection... [Read more...]

Industry
Biotechnology
IPO Date
Oct 25, 2019
Stock Exchange
NASDAQ
Ticker Symbol
PHAT
Full Company Profile

Financial Performance

Financial Statements

Analyst Forecasts

According to 3 analysts, the average rating for PHAT stock is "Buy." The 12-month stock price forecast is 58.17, which is an increase of 71.14% from the latest price.

Price Target
$58.17
(71.14% upside)
Analyst Consensus: Buy